Endpoints are typically determined during the design phase of a clinical trial. Researchers consider factors like the type and stage of cancer, the goals of the study, and the characteristics of the patient population. Regulatory agencies, such as the FDA and EMA, often provide guidelines on suitable endpoints for different types of cancer trials.
